Popular Articles
Today Week Month Year

Alnylam Pharmaceuticals claims Pfizer, Moderna infringed on its patent rights to make COVID-19 vaccines
By Arsenio Toledo // Jul 20, 2022

Alnylam Pharmaceuticals has escalated its patent fight against Pfizer and Moderna, claiming that the Wuhan coronavirus (COVID-19) vaccines of the two companies have infringed on its recently acquired patent.


This recent escalation in the patent fight is over the messenger RNA (mRNA) technology used by Pfizer and Moderna in developing their respective COVID-19 vaccines. Alnylam originally filed separate lawsuits against each of them back in March.

On July 12, Alnylam submitted additional documents to reinforce its case against both Big Pharma companies in the U.S. District Court for the District of Delaware. These new documents claim that Pfizer and Moderna's mRNA delivery systems violate Alnylam's patent on lipid nanoparticle technology for delivering genetic material into human cells and how these lipid nanoparticles are manufactured. (Related: BOMBSHELL: Fauci owns patent on SARS-CoV-2 gp120 HIV insertion, which destroys the body's cancer-killing T cells.)

Patent No. 11,246,933 covers "a breakthrough class of cationic biodegradable lipids used to form lipid nanoparticles that carry and deliver" mRNA-based vaccines.

The U.S. Patent and Trademark Office granted the patent to Alnylam on the same day the pharmaceutical company filed its additional complaints in federal court. Alnylam claimed in all of its lawsuits that its technology is "essential" to the COVID-19 vaccines.

The company is seeking royalties from the sale of the COVID-19 vaccines. Alnylam is not seeking to pull Pfizer and Moderna's COVID-19 vaccines from the market.

Alnylam is just the latest biotechnology company to file a patent lawsuit this year over the lipid nanoparticle technology in Pfizer and Moderna's COVID-19 vaccines. CureVac, a German pharmaceutical company that specializes in mRNA-based treatments, earlier sued BioNTech, Pfizer's German partner in developing the COVID-19 vaccine, claiming that four of its patents were infringed.

Moderna, Pfizer deny allegations of patent infringement

In response to the recent lawsuit, Moderna responded by referring to a statement posted on its website back in May when it moved to dismiss Alnylam's claim, contending that the suit was not appropriate for a district court.

"Under federal law, claims against U.S. government-contracted suppliers must proceed against the government in the U.S. Court of Federal Claims," wrote Moderna. The law the company is referencing provides protections for authorized government contractors like Moderna.

"Moderna's lipids do not resemble Alnylam's work," the company added. "Any assertion that the Alnylam patent covers Moderna's COVID-19 vaccine is specious and, as a result, Alnylam's claims will fail even if Alnylam complies with the statutory requirements and refiles in the Court of Federal Claims against the U.S. government."

As of press time, Pfizer has not responded to Alnylam's recent lawsuit. But Pfizer commented on Alnylam's original claim by saying that the company's patent played no role in the success of its COVID-19 vaccine, and that its vaccine "falls outside the scope of what Alnylam actually invented." Pfizer also called Alnylam's attempt to take it to court over alleged patent rights a clear-cut case of seeking improper economic benefits.

Both Pfizer and Moderna have made tens of billions of dollars each in sales from their COVID-19 vaccines. Pfizer anticipates earning $32 billion in vaccine sales this year, and Moderna predicts $21 billion in vaccine sales. Any successful infringement claims, either from Alnylam or any other pharmaceutical company whose patent rights were allegedly violated, could end up being very lucrative.

Learn more about Big Pharma companies at BigPharmaNews.com.

Watch this clip of Moderna CEO Stephane Bancel confessing to having patented the COVID-19 spike protein more than three years before the pandemic.

This video is from the InfoWars channel on Brighteon.com.

More related articles:

Pfizer petitions court to dismiss whistleblower lawsuit because government was fully aware of fraud when agreeing to work with company.

More evidence emerges indicating that COVID-19 was "manufactured" in a Chinese lab, then Moderna patented it.

NIH claims co-ownership of Moderna COVID vaccine patent, demonstrating how taxpayer money is used to develop therapeutics that make drug companies wealthy.

Report says Chinese scientist filed for a coronavirus vaccine patent BEFORE the pandemic.

FOUL PLAY? Military scientist funded by Fauci died mysteriously after filing covid vaccine patent.

Sources include:





Related News
Take Action:
Support NewsTarget by linking to this article from your website.
Permalink to this article:
Embed article link:
Reprinting this article:
Non-commercial use is permitted with credit to NewsTarget.com (including a clickable link).
Please contact us for more information.
Free Email Alerts
Get independent news alerts on natural cures, food lab tests, cannabis medicine, science, robotics, drones, privacy and more.

NewsTarget.com © 2022 All Rights Reserved. All content posted on this site is commentary or opinion and is protected under Free Speech. NewsTarget.com is not responsible for content written by contributing authors. The information on this site is provided for educational and entertainment purposes only. It is not intended as a substitute for professional advice of any kind. NewsTarget.com assumes no responsibility for the use or misuse of this material. Your use of this website indicates your agreement to these terms and those published on this site. All trademarks, registered trademarks and servicemarks mentioned on this site are the property of their respective owners.

This site uses cookies
News Target uses cookies to improve your experience on our site. By using this site, you agree to our privacy policy.
Learn More
Get 100% real, uncensored news delivered straight to your inbox
You can unsubscribe at any time. Your email privacy is completely protected.